Isomab review finds no increased cancer or retinopathy risk across 11 studies
AI Summary- Isomab reported a systematic review of clinical trials testing proangiogenic therapies.
- 11 studies covered 636 patients, with follow-up lasting two to 12 years.
- Isomab plans to advance ISM-001 toward first-in-human trials in refractory chronic-angina patients.